Elekta Evo: Revolutionising Personalised Cancer Care
Berlin’s Diagnostisch Therapeutisches Zentrum (DTZ) has made history as the first facility in the world to treat a patient using Elekta Evo, an AI-powered adaptive CT-Linac.
This groundbreaking milestone was achieved in the treatment of a 62-year-old male patient diagnosed with bladder cancer, showcasing a significant leap in personalised cancer care.
The Elekta Evo system integrates high-definition, AI-enhanced imaging with cutting-edge automation, enabling real-time treatment planning through online adaptive radiation therapy.
With Evo, clinicians can visualise tumours and organs-at-risk with exceptional clarity, enhancing precision and efficiency in cancer treatment. The advanced system offers a transformative approach, making radiation therapy not only more effective but also more comfortable for patients.
A Radiation Oncologist and partner at DTZ highlighted the revolutionary impact of Evo’s AI-driven imaging feature, Iris, which significantly enhances cone beam CT (CBCT) image quality.
AI-enhanced image reconstruction gives them greater confidence in their work and saves valuable time, improving both treatment quality and patient comfort. Evo’s capacity for faster dose calculation and AI-driven contouring and dose planning means that clinicians can offer patients highly tailored treatments with remarkable efficiency.
DTZ, known for its pioneering use of diagnostic and therapeutic oncology technology, has integrated Elekta Evo into its comprehensive suite of radiotherapy solutions. These include five state-of-the-art linear accelerators and a range of Elekta ONE software tools, which collectively provide advanced image-guided radiation therapy.
Furthermore, this robust system allows clinicians to select the most appropriate treatment technique for each patient, incorporating both online and offline plan adaptation for optimal outcomes.
The patient undergoing this landmark treatment chose radiation therapy with Elekta Evo as a less invasive alternative to traditional surgery, which can be significantly more disruptive to quality of life.
With Evo’s high precision and adaptability, this approach underscores the potential for radiation therapy to offer transformative results without the invasiveness of surgery.
Elekta’s President and CEO expressed pride in DTZ’s adoption of Evo, stating that DTZ has a long-standing reputation for providing the latest diagnostic and therapeutic oncology technology.
Evo is facilitating personalised radiotherapy for cancer patients, and they are excited to see more sites begin treatments soon. The President further emphasised Elekta’s commitment to delivering the best imaging and treatment tools, noting the satisfaction of seeing Evo make personalised radiotherapy a tangible reality for patients.
Conclusion
The introduction of Elekta Evo at DTZ marks a pivotal moment in the evolution of cancer care, offering unmatched precision, adaptability, and patient comfort.
By combining Artificial Intelligence-powered imaging, advanced automation, and real-time treatment planning, Evo is setting a new benchmark in personalised radiation therapy.
As more treatment centres embrace this revolutionary technology, the future of cancer care looks brighter, with patients like DTZ’s trailblazing bladder cancer patient leading the way to a new era of hope and healing.
News Credits: German cancer centre treats first patient with Elekta Evo
Things you may also like: